These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34208264)

  • 1. Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.
    Kwan A; Winder N; Muthana M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34208264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.
    Sostoa J; Dutoit V; Migliorini D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.
    Liu H; Luo H
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34198859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
    Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
    Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
    Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses-immunotherapeutics on the rise.
    Keller BA; Bell JC
    J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virotherapy Research in Germany: From Engineering to Translation.
    Ungerechts G; Engeland CE; Buchholz CJ; Eberle J; Fechner H; Geletneky K; Holm PS; Kreppel F; Kühnel F; Lang KS; Leber MF; Marchini A; Moehler M; Mühlebach MD; Rommelaere J; Springfeld C; Lauer UM; Nettelbeck DM
    Hum Gene Ther; 2017 Oct; 28(10):800-819. PubMed ID: 28870120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy.
    Kennedy BE; Sadek M; Gujar SA
    Mol Ther; 2020 Jun; 28(6):1417-1421. PubMed ID: 32243836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus-based combination therapy in breast cancer.
    Bahreyni A; Mohamud Y; Luo H
    Cancer Lett; 2024 Mar; 585():216634. PubMed ID: 38309616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic viruses: now interviewing for the all-star game.
    Vile R
    Mol Ther; 2010 May; 18(5):866-8. PubMed ID: 20436492
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Oncolytic Viruses: A Systematic Review.
    Cook M; Chauhan A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy for urological cancers.
    Delwar Z; Zhang K; Rennie PS; Jia W
    Nat Rev Urol; 2016 Jun; 13(6):334-52. PubMed ID: 27215429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.